Results 111 to 120 of about 95,577 (390)

Acting without being in control: Exploring volition in Parkinson's disease with impulsive compulsive behaviours. [PDF]

, 2017
BACKGROUND: Several aspects of volitional control of action may be relevant in the pathophysiology of impulsive-compulsive behaviours (ICB) in Parkinson's disease (PD).
de Boer, L, Edwards, MJ, Haggard, P, Morgante, F, Ricciardi, L, Sorbera, C, Stenner, M-P   +6 more
core   +2 more sources

Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo®)

Neuropsychiatric Disease and Treatment, 2010
Paolo Solla, Antonino Cannas, Francesco Marrosu, Maria Giovanna MarrosuMovement Disorders Center, Institute of Neurology, University of Cagliari, Cagliari, ItalyAbstract: Parkinson disease (PD) is a neurodegenerative disorder characterized by 3 cardinal ...
Paolo Solla, Antonino Cannas, Francesco Marrosu, et al   +3 more
doaj  

Cardiovascular autonomic function and MCI in Parkinson's disease [PDF]

, 2019
Introduction: dysautonomic dysfunction and cognitive impairment represent the most disabling non-motor features of Parkinson's Disease (PD). Recent evidences suggest the association between Orthostatic Hypotension (OH) and PD-Dementia. However, little is
Baschi R., Cicero C. E., Davi M., Donzuso G., Giuliano L., Luca A., Monastero R., Mostile G., Nicoletti A., Raciti L., Sciacca G., Terravecchia C., Zappia M.   +12 more
core   +1 more source

Clinical and Imaging Correlates of Medication Reduction in Globus Pallidus Stimulation for Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background The magnitude and factors associated with levodopa equivalent daily dose (LEDD) reduction in deep brain stimulation (DBS) of the globus pallidus interna (GPi) for Parkinson's Disease (PD) remain unclear. Objective To investigate LEDD reduction in GPi DBS and its correlation with anatomical/clinical characteristics.
Daniel G. Di Luca, Carolina Ramirez‐Gomez, Brendan Santyr, Marco Fumagalli, Jürgen Germann, Suneil K. Kalia, Andres M. Lozano, Alfonso Fasano   +7 more
wiley   +1 more source

Levodopa-Induced Changes in Electromyographic Patterns in Patients with Advanced Parkinson’s Disease

Frontiers in Neurology, 2018
Levodopa medication is the most efficient treatment for motor symptoms of Parkinson’s disease (PD). Levodopa significantly alleviates rigidity, rest tremor, and bradykinesia in PD.
Verneri Ruonala, Eero Pekkonen, Olavi Airaksinen, Markku Kankaanpää, Pasi A Karjalainen, Saara M Rissanen   +5 more
doaj   +1 more source

Progress Notes : a report from the Parkinson's Disease Center at Boston University Medical Center [PDF]

, 1989
News and updates from the Boston University Medical Center, Parkinson's Disease ...
Parkinson's Disease Center at Boston University Medical Center
core   +3 more sources

Costs of Parkinson's Disease and Antiparkinsonian Pharmacotherapy: An Italian Cohort Study [PDF]

, 2010
Objective: Antiparkinsonian pharmacotherapy is costly and the determinants of drug costs in Parkinson's disease (PD) have been poorly investigated. The objective of this study was to investigate the costs of PD and antiparkinsonian drugs in an Italian ...
Balzer-Geldsetzer, Monika, Barone, Paolo, Bötzel, Kai, Campenhausen, Sonja von, Dodel, Richard, Eggert, Karla, Longo, Katia, Oertel, Wolfgang H., Reese, Jens P., Spiga, Giuseppe, Winter, Yaroslav   +10 more
core   +1 more source

Salience and default mode network coupling predicts cognition in aging and Parkinson’s disease [PDF]

, 2016
OBJECTIVES: Cognitive impairment is common in Parkinson’s disease (PD). Three neurocognitive networks support efficient cognition: the salience network, the default mode network, and the central executive network.
Cronin-Golomb, Alice, Janes, Amy C., Putcha, Deepti, Ross, Robert S., Stern, Chantal E.   +4 more
core   +1 more source

Prevalence and Clinical Characteristics of the LRRK2 p.L1795F Variant in Central Europeans with Early‐Onset and Familial Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Leucine‐rich repeat kinase 2 (LRRK2) p.L1795F variant was proposed as a genetic risk factor for Parkinson's disease (PD). However, its prevalence, phenotype, and origin remain unknown. Objective The aim was to evaluate the frequency and phenotype of p.L1795F in early‐onset PD (EOPD) and familial PD compared to healthy controls (HC ...
Miriam Ostrozovicova, Gertrud Tamas, Agsha Atputhavadivel, Petr Dusek, Milan Grofik, Vladimir Han, Petr Holly, Robert Jech, Katarina Kalinova, Peter Klivenyi, Norbert Kovacs, Kristina Kulcsarova, Egon Kurca, Alexandra Lackova, Hamin Lee, Patrick Lewis, Veronika Magocova, Maria Marekova, David Murphy, Ai Nagano, Jan Necpal, David Pinter, Miroslava Rabajdova, Evzen Ruzicka, Tereza Serranova, Katarzyna Smilowska, Krisztina Soos, Igor Straka, Tatiana Svorenova, Peter Valkovic, Katerina Zarubova, Zuzana Gdovinova, Henry Houlden, Mie Rizig, Matej Skorvanek, on behalf of the CEGEMOD consortium   +35 more
wiley   +1 more source

Impact of Istradefylline on Levodopa Dose Escalation in Parkinson’s Disease: ISTRA ADJUST PD Study, a Multicenter, Open-Label, Randomized, Parallel-Group Controlled Study

Neurology and Therapy
Introduction A higher levodopa dose is a risk factor for motor complications in Parkinson’s disease (PD). Istradefylline (IST) is used as adjunctive treatment to levodopa in PD patients with off episodes, but its impact on levodopa dose titration remains
Taku Hatano, Renpei Sengoku, Hiroshi Nagayama, Naotake Yanagisawa, Asako Yoritaka, Keisuke Suzuki, Noriko Nishikawa, Yohei Mukai, Kyoichi Nomura, Norihito Yoshida, Morinobu Seki, Miho Kawabe Matsukawa, Hiroo Terashi, Katsuo Kimura, Jun Tashiro, Shigeki Hirano, Hidetomo Murakami, Hideto Joki, Tsuyoshi Uchiyama, Hideki Shimura, Kotaro Ogaki, Jiro Fukae, Yoshio Tsuboi, Kazushi Takahashi, Toshimasa Yamamoto, Kenichi Kaida, Ryoko Ihara, Kazutomi Kanemaru, Osamu Kano   +28 more
doaj   +1 more source